key: cord-0698292-31sg0duh
authors: Viazelda, A. T.; Rudiansyah, M.
title: POS-917 COVID-19 CAUSED CHRONIC KIDNEY DISEASE
date: 2022-02-28
journal: Kidney International Reports
DOI: 10.1016/j.ekir.2022.01.956
sha: 12d406984466065f4bfeb9d56ab42f441c4e7525
doc_id: 698292
cord_uid: 31sg0duh

nan

$ Delayed presentation to the health care unit and symptomatic illness at admission also significantly contributed to mortality in the second wave of covid. Introduction: After 2 years, the COVID-19 virus continues to ravage the world. Initial studies have shown increased susceptibility of chronic kidney disease patients to severe infection and mortality. We aim to determine the risk factors for inpatient mortality amongst hospitalised COVID-19 patients with kidney disease. Methods: This is an observational cohort study involving all patients diagnosed with COVID-19 infection with kidney disease in the first quarter of 2021. Kidney disease refers to end stage kidney disease, chronic kidney disease and acute kidney injury. Relevant clinical and demographic data was extracted from the electronic medical records and statistical analysis was conducted using SPSS version 26. Multivariate logistic regression was performed to determine risk factors associated with mortality amongst patients with kidney disease. Conclusions: COVID-19 mortality rate remains high amongst those with ESKD, CKD and AKI. Older age, premorbid kidney disease, raised peak serum sodium, higher category of illness, mechanical ventilation and unknown epidemiology link increases its risk. Future studies should evaluate the incidence and outcome of COVID-19 infection in patients with kidney disease post vaccination. In January 2021, the ultrasound showed normal kidney, and current ultrasound showed blurriness in parenchymal cortex of kidney that indicated a chronic parenchymal disease bilateral. Patient was diagnosed a CKD stage V and underwent renal replacement therapy with hemodialysis.

Results: In COVID-19 there is inflammatory reaction caused by the cytokine storm during infection. 1 Those iinfected cell can be recognized by T-cells and B-cells, and it can trigger an apoptosis to protect the body from virus. This inflammation produces vasoactive mediators in the form of increased angiotensin II and decreased nitrite oxidation which reduces nephron function. 3 The urinalysis results those supported the inflammatory conditions in the patient's tubulointerstitial and glomerulointerstitial. The decline of GFR will be even more severe and leads to decrease functional of tubuloand glomerulo-interstitial, so makes salt retention and edema. Patient's age and his hypertension history could worse kidney condition after the COVID-19. Inflammation after COVID-19 causes stiffness of the aorta and blood vessels so that blood flow will be disrupted and exacerbated cardiovascular disorders that have previously occurred. Introduction: Immunocompromised patients are particularly at increased risk of getting severe Covid-19 infection and this includes patients with renal transplant. Thus, it is pivotal for this group of patients to receive Covid-19 vaccination which was shown to reduce morbidity and mortality. However, this cohort of patients may have vaccine hesitancy as these vaccines were not tested among renal transplant recipients in clinical trials. There were also reports of acute renal allograft rejection following Covid-19 vaccination. It is the aim of this study to evaluate the adverse events of Covid-19 vaccines and their severity among renal transplant recipients. Methods: All renal transplant recipients under follow-up in Selayang Hospital who had completed Covid-19 vaccination were included in this study. The demographic data and details of these patients were recorded. Phone calls were made between 15 th to 19 th September 2021 to conduct the interview. They were asked to report any adverse events within the first week after first and/or second dose of vaccination. The severity of each symptom was also recorded. Mild adverse events were regarded as discomfort that did not limit oneself from performing usual daily chores, moderate adverse events were those that limited daily activities whilst severe adverse events were those that required medical treatment. Presence of biopsy-proven acute rejection within the first three months following Covid-19 vaccination was also recorded. Results: Out of a total of 151 renal transplant recipients, 67 were managed to be contacted and consented to take part in this study. There were 38 male (56.7%) and 29 female (43.3%) patients with a mean age of 47.7 (SD 14.2) years old. Forty-seven percent was Malay, 43% was Chinese while 10% was Indian. Among them, 92.5% were on prednisolone, 92.5% on calcineurin inhibitors, 71.6% on mycophenolic acid, and 29.9% on everolimus. A majority of 94% patients received Pfizer-BioNTech Covid-19 vaccine (Comirnaty ) while 6% received Sinovac Covid-19 vaccine (Coro-naVac ).

The three most common adverse events reported were injection site reaction (73.1%) followed by fatigue (46.3%) and dizziness (20.9%). Besides, patients also experienced fever (16.4%), headache (16.4%) and myalgia (14.9%). Only 3% of the patients had allergic reaction while 9% experienced other adverse events such as acute renal allograft rejection and infections.

A total of five patients (7.5%) developed severe adverse events. The first patient developed borderline T-cell-mediated rejection six weeks after second dose of Comirnaty vaccine. The second patient sustained left arm cellulitis at the site of vaccine administration, one week after second dose of Comirnaty vaccine. The third patient had shingles over left T11 dermatome, four days after second dose of Comirnaty vaccine. The fourth patient developed allergic rash a few hours following second dose of Comirnaty vaccine. The last patient developed dizziness and had a fall a few hours after his second dose of CoronaVac vaccine. He did not sustain any fracture or haematoma from the fall. Conclusions: Most of the adverse events that occurred following Covid-19 vaccination were mild in nature. However, further study with more patients were needed to evaluate the risk of severe adverse events resulted from Covid-19 vaccination among renal transplant recipients.

No conflict of interest

COVID-19 and Kidney Diseases in Indonesia

Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19

Clinical Practice for Acute Kidney Injury